Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1103 in advanced solid tumors
NCT05884801Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS1103 in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Dose for Phase II at 24 months and 1 more. Status: unknown.
02
Drugs
QLS1103
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05884801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884801.